USE OF IPRONIAZID IN NONTUBERCULOUS BONE AND JOINT INFECTIONS

Abstract

Iproniazid (Marsilid) is a newly developed chemical similar in structural formula to isoniazid (Rimifon, Nydrazid, etc.). It is still restricted to experimental use only and has not been released for general use. Its use and its benefits have been well established in tuberculous bone and joint lesions and reported in detail. Its efficacy in the treatment of tuberculous bone and joint lesions, as compared with that of isoniazid, has been investigated and reported. Though more toxic than isoniazid, iproniazid is much more effective, and its toxic effects can be controlled. No permanent damage has resulted from its use in over 100 cases, as regards either impairment of liver function or development of psychosis, the two major complications. During the experimental use of iproniazid in cases of bone and joint tuberculosis, many side-effects were noted. The clinical beneficial responses seen were reduction of temperature, marked increase in appetite, gain in weight,